MAP Pharmaceuticals Inc. MAP Pharmaceuticals Inc. Latest from The Business Journals A new hope for migraine sufferers?New hope for migraine sufferers?Map Pharmaceuticals swings to .6M profit in Q1 Follow this company will be paid $20 million by partner Allergan Inc. Allergan Inc. Latest from The Business Journals Brisbane biotech nabs M for dry eye drugAllergan to buy Vicept, developer of experimental rosacea treatmentAllergan to buy Vicept, developer of experimental rosacea treatment Follow this company for filing a drug application with the Food and Drug Administration. Mountain View-based MAP (NASDAQ: MAPP) said the FDA accepted its application for the inhaled migraine drug Levadex. The successful submission of that application triggers a $20 million milestone payment under MAP’s deal with Allergan.
